MRK vs PAVM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
PAVM exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9 and a catastrophic Current Ratio of 0.17, indicating a severe liquidity crisis. While revenue growth is nominally high (420%), the operational efficiency is non-existent with an operating margin of -13,082.69% and negative gross margins. There is a profound disconnect between the fundamental collapse (99.5% 5-year price decline) and the optimistic analyst target price of $40.50. The company is currently operating in a state of extreme financial fragility with no evidence of sustainable profitability.
Compare Another Pair
Related Comparisons
MRK vs PAVM: Head-to-Head Comparison
This page compares Merck & Co., Inc. (MRK) and PAVmed Inc. (PAVM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.